HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers

References

• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74:2913–2921.
   PubMed Web of Science ®Google Scholar
• Holly EA, Chaliha I, Bracci PM, et al. Signs and symptoms of pancreatic cancer: a population-based case–control study in the San Francisco Bay area. Clin Gastroenterol Hepatol. 2004;2:510–517.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607–620.
   PubMed Web of Science ®Google Scholar
• Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606–1625.
   PubMed Web of Science ®Google Scholar
• Ju HQ, Gocho T, Aguilar M, et al. Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation. Mol Cancer Ther. 2015;14:788.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. JCO. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Azevedo S, Okusaka T, et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol. 2015;26:921–927.
   PubMed Web of Science ®Google Scholar
• Celia C, Cosco D, Paolino D, et al. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin Drug Deliv. 2011;8:1609–1629.
   PubMed Web of Science ®Google Scholar
• De Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16.
   PubMed Web of Science ®Google Scholar
• Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des. 2008;14:1124–1137.
   PubMed Web of Science ®Google Scholar
• Le UM. Advancement in gemcitabine delivery for cancer treatment. IFMBE Proc. 2015;46:51.
   Google Scholar
• Choi JY, Ramasamy T, Tran TH, et al. Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth. J Mater Chem B. 2015;3:408–416.
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Haidar ZS, Tran TH, et al. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 2014;10:5116–5127.
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Choi JY, et al. Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells. Int J Nanomed. 2015;10:5249.
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Li C, et al. The nuclear epidermal growth factor receptor signalling network and its role in cancer. Discov Med. 2011;12:419–432.
   PubMed Web of Science ®Google Scholar
• Masuda H, Zhang D, Bartholomeusz C, et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136:331–345.
   PubMed Web of Science ®Google Scholar
• Master AM, Gupta AS. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine. 2012;7:1895–1906.
   PubMed Web of Science ®Google Scholar
• Mickler FM, Möckl L, Ruthardt N, et al. Tuning nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand. Nano Lett. 2012;12:3417–3423.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19:1978–1985.
   PubMed Web of Science ®Google Scholar
• Schäfer A, Pahnke A, Schaffert D, et al. Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum Gene Ther. 2011;22:1463–1473.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485–490.
   PubMed Web of Science ®Google Scholar
• Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 2012;19:367.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li F, Li Y, et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials. 2015;46:13–25.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schwerbrock NM, Rogers AB, et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther. 2013;21:1559–1569.
   PubMed Web of Science ®Google Scholar
• Xu J, Amiji M. Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles. J Vis Exp. 2012;59:3612.
   Google Scholar
• Oh YK, Park TG. SiRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61:850–862.
   PubMed Web of Science ®Google Scholar
• Abourbeh G, Shir A, Mishani E, et al. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life. 2012;64:324–330.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J Off Publ Fed Am Soc Exp Biol. 2005;19:1978–1985.
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Ruttala HB, Gupta B, et al. Smart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive review. J Control Release. 2017;258:226–253.
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Ruttala HB, Sundaramoorthy P, et al. Multimodal selenium nanoshell-capped Au@mSiO2 nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer. NPG Asia Mater. 2018;10:197–216.
   Web of Science ®Google Scholar